共 41 条
- [31] Effect of immunotherapy of triple negative breast cancer with ROR1 CAR T cells in combination with the TGF-β receptor I kinase inhibitor SD-208JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)Stuber, TanjaMonjezi, RaziehWoeckel, AchimEinsele, HermannWischhusen, JoergHudecek, Michael
- [32] An orally active inhibitor of the TGF-β type I receptor, ALK5, adventitial myofibroblast induction, and vascular remodeling in the rat carotid balloon injury modelARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2007, 27 (06) : E82 - E82Fu, KaiCorbley, Michael J.Sun, LihongFriedman, JessicaShan, FengPapadatos, James L.Costa, DonaldLutterodt, FrankSweigard, HarryReis, JeannieKorsman, PamelaBowes, ScottChol, MichaelBoriack-Sjodin, AnnArduini, RobertSun, DongyuZhang, XiameiMead, JonathanChuaqui, ClaudioCheung, KamZhang, XinCornebise, MarkJosiah, SereneSingh, JuswinderLee, Wen-CherngGill, AlanLing, Leona E.
- [34] EW-7203, a novel small molecule inhibitor of transforming growth factor-β (TGF-β) type I receptor/activin receptor-like kinase-5, blocks TGF-β1-mediated epithelial-to-mesenchymal transition in mammary epithelial cellsCANCER SCIENCE, 2011, 102 (10) : 1889 - 1896Park, Chul-YongKim, Dae-KeeSheen, Yhun Yhong
- [35] Vactosertib, a Novel Transforming Growth Factor Beta (TGFβ) Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness: A Single-Arm, Phase Ib Trial in Relapsed or Refractory Multiple Myeloma (RRMM)CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S505 - S506Malek, EhsanRana, PriyankaDaunov, MichaelMiyagi, MasaruIgnatz-Hoover, JamesMetheny, LelandDriscoll, James
- [36] Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)BLOOD, 2015, 126 (23)Moreau, PhilippeMasszi, TunasGrzasko, NorbertBahlis, Nizar J.Hansson, MarkusPour, LudekSandhu, IrwindeepGanly, PeterBaker, Bartrum W.Jackson, SharonStoppa, Anne -MarieSimpson, David R.Gimsing, PeterPalumbo, AntonioGarderet, LaurentCavo, MicheleKumar, Shaji K.Touzeau, CyrilleBuadi, FrancisLaubach, Jacob P.Lin, JianchangBerg, DeborahDiBacco, AlessandraHui, Ai -MinRichardson, Paul G.
- [37] Combination of Anti-PD-L1 Antibody with IMiD® Immunomodulatory Drugs, HDAC Inhibitor ACY-1215, Bortezomib, or Toll-like Receptor 9 Agonist Enhances Anti-Tumor Immunity and Cytotoxicity in Multiple MyelomaBLOOD, 2015, 126 (23)Ray, ArghyaDas, Deepika SharmaSong, YanChauhan, DharminderAnderson, Kenneth C.
- [38] Vactosertib, a Novel TGFb Type I Receptor Kinase Inhibitor, Improves T-Cell Fitness:a Single-Arm, Phase 1b Trial in Relapsed/Refractory Multiple MyelomaBLOOD, 2023, 142Malek, EsanRana, Priyanka S.Swamydas, MuthulekhaDaunov, MichaelMiyagi, MasaruMurphy, ElenaIgnatz-Hoover, James J.Metheny, LelandKim, Seong-JinJames, Driscoll J., II
- [39] Safety interim data front a three-arm phase II study evaluating safety and pharmacokinetics of the oral transforming growth factor-beta (TGF-β) receptor I kinase inhibitor LY2157299 monohydrate in patients with glioblastoma at first progression.JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)Carpentier, Antoine F.Brandes, Alba ArielaKesari, SantoshSepulveda, Juan ManuelWheeler, HelenChinot, Oliver L.Cher, LawrenceSteinbach, Joachim PeterSpecenier, Pol M.Cleverly, AnnTomlin, IreneDesaiah, DurisalaLahn, Michael M. F.Wick, Wolfgang
- [40] A phase 1b/2 dose escalation and cohort expansion study of the safety, tolerability and efficacy of a transforming growth factor-beta (TGF-β) receptor I kinase inhibitor (galunisertib) in combination with anti-PD-1 (nivolumab) in advanced refractory solid tumoursANNALS OF ONCOLOGY, 2016, 27Guba, S. C.Mukhopadhyay, S.Desaiah, D.Andre, V. A. M.